Company profile for Rexahn Pharmaceuticals Inc

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Rexahn Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of cancer. Our mission is to extend and improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects normally associated with cancer treatment. Rexahn is focused on discovering...
Rexahn Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of cancer. Our mission is to extend and improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects normally associated with cancer treatment. Rexahn is focused on discovering and developing new treatments that have the potential to improve the clinical outcome in cancers that are difficult to treat.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
15245 Shady Grove Road, Suite 455 Rockville, MD 20850
Telephone
Telephone
+ 240-268-5300
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.biospace.com/article/releases/rexahn-pharmaceuticals-announces-expected-effectiveness-of-reverse-stock-split-and-merger-transaction-with-ocuphire-pharma/?s=79

BIOSPACE
05 Nov 2020

https://www.biospace.com/article/releases/rexahn-and-ocuphire-enter-into-definitive-merger-agreement/?s=79

BIO SPACE
18 Jun 2020
Rexahn licenses pancreatic cancer drug candidate in China
Rexahn licenses pancreatic cancer drug candidate in China

19 Apr 2019

// Maggie Lynch IN-PHARMATECHNOLOGIST

https://www.in-pharmatechnologist.com/Article/2019/04/18/Rexahn-licenses-pancreatic-cancer-drug-candidate-in-China

Maggie Lynch IN-PHARMATECHNOLOGIST
19 Apr 2019

https://www.globenewswire.com/news-release/2019/04/16/1804668/0/en/Rexahn-and-BioSense-Global-Announce-Collaboration-and-License-Agreement-for-RX-3117-in-Greater-China.html

GLOBENEWIRE
16 Apr 2019

https://www.nasdaq.com/press-release/bioxcel-therapeutics-enhances-leadership-with-appointment-of-vikas-sharma-phd-as-vice-president-of-20180731-00676

NASDAQ
31 Jul 2018

https://trueindustrynews.com/global-renal-cell-cacinoma-drugs-market-overview-2018-rexahn-pharmaceuticalsbionomicscerulean-pharma-inccelldex-therapeuticstvax-biomedicaltracon-pharmaceuticals/

TRUEINDUSTRY
29 Jul 2018

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty